This article discusses a first-in-human, early-stage clinical trial that involved injecting brain stem cells directly into the brains of 15 patients with secondary progressive MS. The stem cells were obtained from a single miscarried foetus and extensively screened for anomalies. Participants experienced no severe adverse events after the treatment and did not report relapse-like symptoms of MS or significant deterioration in movement or cognitive function. Analysis showed an association between higher stem cell doses and a reduction in brain volume, suggesting a possible role in preventing brain inflammation.
This article discusses a first-in-human, early-stage clinical trial that involved injecting brain stem cells directly into the brains of 15 patients with secondary progressive MS. The stem cells were obtained from a single miscarried foetus and extensively screened for anomalies. Participants experienced no severe adverse events after the treatment and did not report relapse-like symptoms of MS or significant deterioration in movement or cognitive function. Analysis showed an association between higher stem cell doses and a reduction in brain volume, suggesting a possible role in preventing brain inflammation.
टिप्पणियाँ
एक टिप्पणी भेजें